Stephen Liu, Medical Oncologist, Chief of Hematology and Oncology, Director of Thoracic Oncology, Head of Developmental Therapeutics, Associate Professor of Medicine at Georgetown Lombardi Comprehensive Cancer Center, shared a post on X about a recent article by Martin Wermke et al published in Journal of Clinical Oncology:
“Phase I results of obrixtamig (DLL3-CD3 bispecific T-cell engager) (n=168 SCLC / neuroendocrine carcinoma).
Across doses/cohorts, RR 23%, DOR 8.5m (in large cell neuroendocrine, RR 70%). CRS in 57% (G3+ 3%).
Active challenger to tarlatamab.”
Title: Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas
Authors: Martin Wermke, Valentina Gambardella, Yasutoshi Kuboki, Enriqueta Felip, Miguel F. Sanmamed, Olatunji B. Alese, Cyrus M. Sayehli, Edurne Arriola, Jürgen Wolf, Liza C. Villaruz, Julia Bertulis, Matus Studeny, Mohamed Bouzaggou, Xiaoyan Fang, Daniel Morgensztern
Read the Full Article on Journal of Clinical Oncology
More posts featuring Stephen Liu.